



ATOPIC ECZEMA/DERMATITIS

## EVALUATION OF THE TOLERANCE OF AN ANTI-PRURITUS SPRAY IN FLARE-UP OF ATOPIC DERMATITIS

*Sandrine Virassamynaik<sup>(1)</sup> - Fabienne Alfonsi<sup>(1)</sup> - Julie Riviere<sup>(2)</sup> - Bernard Chadoutaud<sup>(2)</sup> - Michèle Sayag<sup>(1)</sup>*

*Naos - Bioderma, Innovation - R&d Coordination, Lyon, France<sup>(1)</sup> - Clinreal Online, Clinical Trials, Toulouse, France<sup>(2)</sup>*

**Introduction:** Atopic dermatitis (AD) is a pruritic, chronic and inflammatory skin disease characterized by eczema lesions and xerosis. Itching, is a part of what defines AD, which alters the quality of life of the subject, as well as that of the family members. The Skin Relief™ technology associated to enoxolone was developed to have a significant action on pruritus (by inhibition of Thymic Stromal Lymphopoietin released by the keratinocytes, whose level is increased in AD) and so, reducing nerve fibre activation.

**Objective:** The purpose of the study was to evaluate an anti-pruritic spray to calm itching in mild or moderate AD.

**Materials & Methods:** In Spain, an observational and multicentre clinical study was conducted on 50 babies and infants who presented flare-up of mild or moderate AD. 48% of flare-up was treated by topical corticosteroids in association with the spray, then, it was applied alone up to 3 times a day until D21. Tolerance was evaluated at D21 whereas the SCORAD, quality of life and AD's impact on family were assessed on D0 and D21.

**Results:** Of 50 included subjects from 4-month to 5-year old, 48 were analysed. Topical corticosteroids were applied during 10.8 days. The spray was applied 1.6 times a day during 21.9 days on average. The product was well-tolerated in 97.9% patients. The association of topical corticosteroids and the product showed a significant improvement of pruritic state by a decrease of -51% of the SCORAD. Otherwise, a positive impact on quality of life of children and family members was demonstrated by a significant decrease of DLQI (-33%) and DFIQ (-37%) scores between D0 and D21.

**Conclusions:** The study confirms the safety profile of this antipruritic spray in AD patients during flare-up and remission period.

